Medicus Pharma restructures debt and raises capital, cites regained Nasdaq compliance
The company exchanged $10.5 million of notes for preferred shares and raised roughly $4.25 million through a registered offering and private placements, saying the moves lift its equity to levels it believes satisfy.
Medicus Pharma Ltd. disclosed a series of financing transactions completed on November 13, 2026, according to an 8-K filed with the SEC. The company entered into and closed an exchange agreement with Streeterville Capital, LLC, under which $10.5 million in principal amount of its Secured Promissory Note A-1 was partitioned and exchanged for 105,000 non-convertible, non-voting preferred shares at $100 per share.1 The preferred shares carry an 8% annual cumulative dividend paid in kind, are redeemable by the company at $100 per share plus unpaid dividends, and rank ahead of common shares in a liquidation.1
Separately, the company sold 97,973 common shares at $1.72 each and pre-funded warrants for up to 1,646,213 additional shares in a registered direct offering, for aggregate gross proceeds of about $3.0 million.1 Concurrently, Medicus completed private placements of 726,730 common shares for about $1.25 million, led by a $750,000 purchase by Executive Chairman and CEO Dr. Raza Bokhari through a controlled entity.1 The company also noted it had sold about 113,000 shares under its at-the-market program since the quarter ended September 30, 2026, for roughly $0.35 million.1
The filing recaps a May 20, 2026 Nasdaq notice that the company's market value of listed securities had fallen below the $35 million threshold, with a compliance deadline of November 16, 2026.1 The company said that after these transactions its unaudited pro forma shareholders' equity was approximately $3.0 million, and that it believes it has regained compliance with Nasdaq's equity standard.1 However, Nasdaq has not yet confirmed that the company has regained compliance, will continue monitoring, and there is no assurance the exchange will agree or that compliance can be sustained.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.